The purpose of this study is to better understand mental illness and will test the hypotheses that while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam.
This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as schizophrenia, bipolar disorder, and schizoaffective disorder). The study will also enroll eligible participants without any psychiatric illness, to compare their brains.
The study will require participants to have 3-4 sessions over a few weeks. The first session (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the MRI. During the fMRI the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, women of child bearing potential will have a urine pregnancy test, vital signs taken, and asked to complete more qols.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia Bipolar Disorder Healthy Psychosis Schizophreniform Disorders Schizo Affective Disorder | Other: Placebo and fMRI Drug: Lorazepam and fMRI | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 232 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | The two MRI sessions will will be scheduled about 1 week apart. If you are a woman, we may need to schedule the scanning session to coincide with a certain phase of your menstrual cycle. |
Masking: | Double (Participant, Care Provider) |
Masking Description: | Study coordinator and participant are blinded to medication administration. |
Primary Purpose: | Basic Science |
Official Title: | Multi-modal Assessment of GABA Function in Psychosis |
Actual Study Start Date : | January 16, 2020 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2025 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Healthy Controls |
Other: Placebo and fMRI
A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: inactive medication
Drug: Lorazepam and fMRI A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: Ativan
|
Experimental: Early Psychosis patients |
Other: Placebo and fMRI
A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: inactive medication
Drug: Lorazepam and fMRI A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: Ativan
|
Experimental: Schizophrenia or Schizoaffective disorder patients |
Other: Placebo and fMRI
A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: inactive medication
Drug: Lorazepam and fMRI A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: Ativan
|
Experimental: Bipolar disorder patients |
Other: Placebo and fMRI
A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: inactive medication
Drug: Lorazepam and fMRI A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Other Name: Ativan
|
Ages Eligible for Study: | 16 Years to 60 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Early psychosis (EP) patients:
Inclusion Criteria:
Exclusion:
Schizophrenia/schizoaffective and bipolar disorder patients
Inclusion Criteria:
Exclusion:
Healthy control subjects:
Inclusion Criteria:
Exclusion:
Contact: Paula Brayboy, BA | (734) 232-4166 | GABAStudy@med.umich.edu | |
Contact: Laura M Stchur, MSW | 734-936-1323 | lmarine@med.umich.edu |
United States, Michigan | |
University of Michigan | Recruiting |
Ann Arbor, Michigan, United States, 48109 | |
Contact: Laura Stchur, MSW 734-936-1323 lmarine@med.umich.edu | |
Principal Investigator: Stephan Taylor, MD |
Principal Investigator: | Stephan Taylor, MD | University of Michigan |
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 28, 2019 | ||||||||||||||||
First Posted Date ICMJE | July 2, 2019 | ||||||||||||||||
Last Update Posted Date | February 17, 2021 | ||||||||||||||||
Actual Study Start Date ICMJE | January 16, 2020 | ||||||||||||||||
Estimated Primary Completion Date | March 2025 (Final data collection date for primary outcome measure) | ||||||||||||||||
Current Primary Outcome Measures ICMJE |
Blood Oxygen level dependent (BOLD) in medial frontal cortex while viewing affective pictures [ Time Frame: 2 hours after ingestion of lorazepam/placebo ] BOLD signal change in medial frontal cortex after lorazepam challenge during fMRI
|
||||||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||
Change History | |||||||||||||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||||||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title ICMJE | Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis | ||||||||||||||||
Official Title ICMJE | Multi-modal Assessment of GABA Function in Psychosis | ||||||||||||||||
Brief Summary |
The purpose of this study is to better understand mental illness and will test the hypotheses that while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam. This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as schizophrenia, bipolar disorder, and schizoaffective disorder). The study will also enroll eligible participants without any psychiatric illness, to compare their brains. The study will require participants to have 3-4 sessions over a few weeks. The first session (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the MRI. During the fMRI the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, women of child bearing potential will have a urine pregnancy test, vital signs taken, and asked to complete more qols. |
||||||||||||||||
Detailed Description | Please note the collaborator (NIMH) is requesting that an NCT number be obtained prior to receiving the award number. | ||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||
Study Phase ICMJE | Phase 4 | ||||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: The two MRI sessions will will be scheduled about 1 week apart. If you are a woman, we may need to schedule the scanning session to coincide with a certain phase of your menstrual cycle. Masking: Double (Participant, Care Provider)Masking Description: Study coordinator and participant are blinded to medication administration. Primary Purpose: Basic Science
|
||||||||||||||||
Condition ICMJE |
|
||||||||||||||||
Intervention ICMJE |
|
||||||||||||||||
Study Arms ICMJE |
|
||||||||||||||||
Publications * | Not Provided | ||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||||||||
Estimated Enrollment ICMJE |
232 | ||||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||||
Estimated Study Completion Date ICMJE | March 2025 | ||||||||||||||||
Estimated Primary Completion Date | March 2025 (Final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria ICMJE |
Early psychosis (EP) patients: Inclusion Criteria:
Exclusion:
Schizophrenia/schizoaffective and bipolar disorder patients Inclusion Criteria:
Exclusion:
Healthy control subjects: Inclusion Criteria:
Exclusion:
|
||||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||||
Ages ICMJE | 16 Years to 60 Years (Child, Adult) | ||||||||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||||||||
Contacts ICMJE |
|
||||||||||||||||
Listed Location Countries ICMJE | United States | ||||||||||||||||
Removed Location Countries | |||||||||||||||||
Administrative Information | |||||||||||||||||
NCT Number ICMJE | NCT04004416 | ||||||||||||||||
Other Study ID Numbers ICMJE | HUM00162597 R01MH118634-01 ( U.S. NIH Grant/Contract ) |
||||||||||||||||
Has Data Monitoring Committee | Not Provided | ||||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||||
Responsible Party | Stephan F. Taylor, University of Michigan | ||||||||||||||||
Study Sponsor ICMJE | University of Michigan | ||||||||||||||||
Collaborators ICMJE | National Institute of Mental Health (NIMH) | ||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||
PRS Account | University of Michigan | ||||||||||||||||
Verification Date | February 2021 | ||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |